Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

ZENAS BIOPHARMA INC (ZBIO)

131 + Investors. Track Smart Money conviction in ZBIO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +46
Streak
6Q ▲
Buyers last Q
75%

Smart Money Signals — ZBIO

Based on 122 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 6 quarters in a row

last 6Q
For 6 consecutive quarters, more hedge funds added ZBIO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
122 hedge funds hold ZBIO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +100% more funds vs a year ago

fund count last 6Q
+61 new funds entered over the past year (+100% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 75% buying

89 buying30 selling
Last quarter: 89 funds were net buyers (52 opened a brand new position + 37 added to an existing one). Only 30 were sellers (24 trimmed + 6 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+41 vs last Q)

new funds entering per quarter
Funds opening a new ZBIO position: 13 → 11 → 11 → 52. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 49% entered in last year

■ 2% conviction (2yr+) ■ 48% medium ■ 49% new
Only 3 funds (2%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +97% but shares only +21% — price-driven

Value
+97%
Shares
+20%
Last quarter: the total dollar value of institutional holdings rose +97%, but actual share count only changed +21%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

33 → 13 → 11 → 11 → 52 new funds/Q
New funds entering each quarter: 13 → 11 → 11 → 52. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🌱

Early stage — 71% of holders entered in last year

■ 5% veterans ■ 24% 1-2yr ■ 71% new
Of 131 current holders: 93 (71%) entered in the past year, only 7 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 30% AUM from major funds

30% from top-100 AUM funds
25 of 122 holders rank in the top 100 by AUM, accounting for 30% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
5.2
out of 10
Moderate Exit Risk
Exit risk score 5.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ZBIO

In 2025 Q4, 89 hedge funds were net buyers of ZBIO (52 opened a new position, 37 added to an existing one), while 30 reduced or exited (24 trimmed, 6 sold completely) — a 75% buyer ratio, indicating clear institutional accumulation. This marks 6 consecutive quarters of net institutional buying — a persistent conviction signal. 30% of total institutional value in ZBIO is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +46 funds (more new holders than closures). Total institutional holders: 122.

Hedge Fund Ownership: ZBIO

How many hedge funds hold ZBIO — quarterly history vs. share price
Quarterly hedge fund ownership of ZBIO vs. share price

Market Analysis: ZBIO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ZBIO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

27 top-rated funds 4 high-conviction
Consensus
6.3
/ 10
breadth
×
Elite
3.4
/ 10
conviction
Hedge Fund Positioning: ZBIO
2026 Q1 Stats Unlock in 5 days 131 + Investors

Track Smart Money conviction in ZBIO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change
Funds Holding 131 76 72.37%
13F Shares 42M 35M 20.76%
Total Value $1.51B $764M 97.4%
New Positions 59 11 +48
Increased Positions 38 23 +15
Closed Positions 6 7 -1
Reduced Positions 24 22 +2
Total Calls 9 1 800.0%
Total Puts 8 0 100%
PUT/CALL Ratio 0.89 0.0 Neutral

Statistics: ZBIO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

131 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ZBIO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 institutional holders of ZBIO — 2025 Q4 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 SR ONE CAPITAL MANAGEMENT, LP 10.76% 5,037,854 $98.5M
2 Pivotal bioVenture Partners Investment Advisor LLC 4.14% 591,991 $11.6M
3 NEXTBio Capital Management LP 3.87% 426,736 $8.3M
4 Fairmount Funds Management LLC 3.33% 2,359,025 $46.1M
5 GREAT POINT PARTNERS LLC 2.35% 524,066 $10.2M
6 SILVERARC CAPITAL MANAGEMENT, LLC 2.27% 1,135,935 $22.2M
7 Monashee Investment Management LLC 1.60% 150,000 $2.9M
8 Sio Capital Management, LLC 0.93% 331,730 $6.5M
9 Exome Asset Management LLC 0.82% 80,730 $1.6M
10 Birchview Capital, LP 0.78% 70,000 $1.4M
11 SPHERA FUNDS MANAGEMENT LTD. 0.67% 214,334 $4.2M
12 Rock Springs Capital Management LP 0.58% 502,077 $9.8M
13 ArrowMark Colorado Holdings LLC 0.34% 658,909 $12.9M
14 Scientech Research LLC 0.21% 12,952 $253K
15 DAFNA Capital Management LLC 0.19% 42,500 $831K
16 Polar Capital Holdings Plc 0.18% 2,548,444 $49.8M
17 Atom Investors LP 0.15% 107,016 $2.1M
18 SEVEN GRAND MANAGERS, LLC 0.13% 100,000 $2.0M
19 FEDERATED HERMES, INC. 0.10% 3,127,031 $61.1M
20 iA Global Asset Management Inc. 0.06% 215,830 $4K
21 Maven Securities LTD 0.06% 150,000 $2.9M
22 Woodline Partners LP 0.04% 590,525 $11.5M
23 FOX RUN MANAGEMENT, L.L.C. 0.04% 13,331 $243K
24 Virtus Investment Advisers, LLC 0.04% 6,717 $131K
25 Jefferies Financial Group Inc. 0.03% 219,947 $4.3M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — ZENAS BIOPHARMA INC (ZBIO)

What does the Smart Money Trend signal show for ZBIO?

Buying streak — 6 quarters in a row: For 6 consecutive quarters, more hedge funds added ZBIO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ZBIO?

More buyers than sellers — 75% buying: Last quarter: 89 funds were net buyers (52 opened a brand new position + 37 added to an existing one). Only 30 were sellers (24 trimmed + 6 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for ZBIO holders?

Strong quality — 30% AUM from major funds: 25 of 122 holders rank in the top 100 by AUM, accounting for 30% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ZBIO?

Mostly new holders — 49% entered in last year: Only 3 funds (2%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.